Nonmelanoma cutaneous cancers involving the skull base: outcomes of aggressive multimodal management
- PMID: 25909577
- DOI: 10.3171/2014.10.jns141037
Nonmelanoma cutaneous cancers involving the skull base: outcomes of aggressive multimodal management
Abstract
Object: A relative paucity of information exists regarding outcomes from craniofacial resection for advanced nonmelanoma skin cancers involving the skull base. In light of advances in surgical technique and adjuvant therapy protocols, the authors reviewed their surgical experience to determine disease control rates, overall survival (OS), morbidity, and mortality.
Methods: A retrospective review of 24 patients with nonmelanoma cutaneous cancers with skull base involvement treated with craniofacial resection at The University of Texas MD Anderson Cancer Center from 1994 to 2012 was performed. Of these patients, 19 (79%) had squamous cell carcinoma (SCC), 4 (17%) had basosquamous carcinoma (BSCC), and 1 patient (4%) had adenocarcinoma. Factors as assessed were prior treatment, TNM staging, tumor involvement, extent of intracranial extension, margin status, postoperative complications, recurrence, disease status at last follow-up, and long-term survival. The majority of tumors were T4 (67%) according to the TNM classification; perineural extension was noted in 58%, cavernous sinus involvement in 25%, and dural involvement in 29%.
Results: Postoperative complications occurred in 4 patients (17%) including 1 death. Kaplan-Meier estimates were calculated for OS and progression-free survival (PFS). Median OS was 43.2 months with an 82% 1-year OS and 37% 5-year OS; the median PFS was 91.2 months. Margin status was positively associated with median OS in SCC (91 months [for negative margins] vs 57 months, p = 0.8) and in BSCC (23.7 vs 3.2 months, p < 0.05). Postoperative radiotherapy was associated with improved median OS (43.2 vs 22 months, p = 0.6). Brain involvement was uniformly fatal after 1 year, while cavernous sinus involvement (31 vs 43 months, p = 0.82), perineural disease (31 vs 54 months, p = 0.30), and T4 stage (22 vs 91.2 months, p = 0.09) were associated with worsened OS. Similar associations were found with median PFS.
Conclusions: Aggressive multimodality management with surgery and postoperative radiotherapy can positively impact locoregional control and OS. With improvements in technique and adjuvant therapy protocols, treatment can still be considered in situations of perineural disease and cavernous sinus involvement and as a salvage option for patients in whom prior treatment has failed. As patients with advanced NMSCs often have few options, craniofacial resection, as part of a coordinated multimodal management plan, is justified if it can be performed safely.
Keywords: BCC = basal cell carcinoma; BSCC = basosquamous cell carcinoma; CN = cranial nerve; MDACC = MD Anderson Cancer Center; NMSC = nonmelanoma skin cancer; OS = overall survival; PFS = progression-free survival; SCC = squamous cell carcinoma; cavernous sinus; craniofacial resection; malignancy; oncology; perineural disease; skin cancer; skull base.
Similar articles
-
Craniofacial resection for nonmelanoma skin cancer of the head and neck.Laryngoscope. 2005 Jun;115(6):931-7. doi: 10.1097/01.MLG.0000163766.66223.97. Laryngoscope. 2005. PMID: 15933497
-
Clinical perineural invasion of the trigeminal and facial nerves in cutaneous head and neck squamous cell carcinoma: Outcomes and prognostic implications of multimodality and salvage treatment.Head Neck. 2017 Jul;39(7):1280-1286. doi: 10.1002/hed.24607. Epub 2017 May 5. Head Neck. 2017. PMID: 28474414
-
Craniofacial Resection for T4 Maxillary Sinus Carcinoma: Managing Cases with Involvement of the Skull Base.Otolaryngol Head Neck Surg. 2015 Aug;153(2):231-8. doi: 10.1177/0194599815586770. Epub 2015 Jun 4. Otolaryngol Head Neck Surg. 2015. PMID: 26044790
-
Squamous Cell Carcinoma and Its Variants.Adv Otorhinolaryngol. 2020;84:124-136. doi: 10.1159/000457932. Epub 2020 Jul 30. Adv Otorhinolaryngol. 2020. PMID: 32731225 Review.
-
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.Cancer. 1999 Apr 15;85(8):1686-93. doi: 10.1002/(sici)1097-0142(19990415)85:8<1686::aid-cncr7>3.0.co;2-7. Cancer. 1999. PMID: 10223561 Review.
Cited by
-
Radiotherapy in the Adjuvant and Advanced Setting of CSCC.Dermatol Pract Concept. 2021 Oct 1;11(Suppl 2):e2021168S. doi: 10.5826/dpc.11S2a168S. eCollection 2021 Nov. Dermatol Pract Concept. 2021. PMID: 34877076 Free PMC article. Review.
-
Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma.JID Innov. 2021 Aug 25;1(4):100045. doi: 10.1016/j.xjidi.2021.100045. eCollection 2021 Dec. JID Innov. 2021. PMID: 34909742 Free PMC article.
-
Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.Cancers (Basel). 2022 Oct 29;14(21):5325. doi: 10.3390/cancers14215325. Cancers (Basel). 2022. PMID: 36358744 Free PMC article. Review.
-
Skull Base Invasion Patterns and Survival Outcomes of Nonmelanoma Skin Cancers.J Neurol Surg B Skull Base. 2017 Apr;78(2):164-172. doi: 10.1055/s-0036-1594239. Epub 2016 Nov 23. J Neurol Surg B Skull Base. 2017. PMID: 28321381 Free PMC article.
-
Localized Non-melanoma Skin Cancer: Risk Factors of Post-surgical Relapse and Role of Postoperative Radiotherapy.Curr Treat Options Oncol. 2020 Oct 9;21(12):97. doi: 10.1007/s11864-020-00792-2. Curr Treat Options Oncol. 2020. PMID: 33034759 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials